Stockreport

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF More than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistamines FDA decision expected by April 18 [Read more]